Severe sepsis in cirrhosis

Area of Science:

• Critical Care Medicine
• Hepatology
• Immunology

Background:

• Sepsis involves a proinflammatory and procoagulant response to pathogens, with stages including sepsis, severe sepsis, and septic shock.
• Cirrhosis patients are highly susceptible to sepsis, sepsis-induced organ failure, and mortality.
• In cirrhosis, sepsis triggers a "cytokine storm," an imbalanced inflammatory response that exacerbates organ damage.

Purpose of the Study:

• To review the pathophysiology and clinical implications of sepsis in patients with cirrhosis.
• To highlight the unique challenges and treatment gaps for severe sepsis in cirrhotic patients.
• To identify potential therapeutic strategies for severe sepsis in the context of cirrhosis.

Main Methods:

• Review of existing literature on sepsis pathophysiology in cirrhosis.
• Analysis of clinical manifestations and organ failures associated with severe sepsis in cirrhotic patients.
• Evaluation of current treatment protocols and their applicability to cirrhotic populations.

Main Results:

• Cirrhosis amplifies the inflammatory response to sepsis, leading to a "cytokine storm" and increased risk of multi-organ failure.
• Specific complications include worsening liver function, shock, renal failure, acute respiratory distress syndrome, coagulopathy, and hepatic encephalopathy.
• While early antibiotics and albumin improve outcomes in spontaneous bacterial peritonitis, evidence for other severe sepsis treatments in cirrhosis is limited.

Conclusions:

• Severe sepsis in cirrhosis is characterized by a dysregulated immune response and a high propensity for organ damage.
• Current treatment guidelines for severe sepsis may not be directly applicable to cirrhotic patients.
• Further randomized controlled trials are crucial to evaluate treatments like antibiotics for non-SBP infections, vasopressors, hydrocortisone, and organ support systems in cirrhotic patients with severe sepsis.